Company Overview
Enveric Biosciences, Inc., a biotechnology company, focuses on the development of small molecule neuroplastogenic therapeutics that address unmet needs in psychiatric and neurological disorders in the United States. Its lead drug candidate is EB-003, a novel derivative of DMT in preclinical development for mental health indications. The company also develops EVM401 series comprising novel phenylalkylamines and indolethylamines, as well as mescaline-derived compounds to target addiction and neuropsychiatric disorders; and Psybrary, a proprietary library. Enveric Biosciences, Inc. is headquartered in Cambridge, Massachusetts.
Recent Developments
- Trailing 12 Months Year-on-year growth — revenue -7.2%.
- 5-Year Trend Long-term compounding — revenue CAGR 3.4%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 3.36% |
| 1 Year: | -7.17% |
Stock Price Performance
| 1 Year: | -89.34% |
| 6 Months: | -28.64% |
| 3 Months: | -18.86% |
| 1 Month: | -8.39% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)48.73 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 91.8% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | ENVB Enveric Biosciences, Inc. PHARMA | 1.42 | -0.12 | $6.36M | 0.00% | - | - | 3.36% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2013 | Jun 2013 | Sep 2013 | Mar 2014 | Jun 2014 | Sep 2014 | Mar 2015 | Jun 2015 | Sep 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 11.02M | 9.15M | - | 8.25M | 8.48M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | 1.08M | - | 1.12M | 982.66K | 1.44M | 1.65M | 1.52M | 1.70M | 3.30M | 2.33M | 2.56M | 2.34M | 2.39M | 2.35M | 2.14M | 2.38M | 1.90M | 1.88M | 1.82M | 1.89M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Income | -4.70K | -3.89K | -4.56K | -7.58K | 575.17K | -3.11K | 1.08M | 179.97K | -315.76K | -981.32K | -936.64K | -1.29M | -630.55K | -3.51M | -3.95M | -1.37M | -1.08M | 6.10M | -1.30M | -1.48M | -1.56M | -836.70K | -767.51K | -489.83K | -6.76M | -3.36M | -3.52M | -4.80M | -4.71M | -5.66M | -4.86M | -5.76M | -3.45M | -2.48M | -1.90M | -2.08M | -2.19M | -2.52M | -1.87M | -1.63M |
| Net Income | -4.70K | -3.89K | -4.56K | -7.87K | 408.37K | -3.18K | 1.08M | 110.97K | -159.55K | -1.16M | -1.21M | -1.78M | -721.99K | -3.28M | -4.07M | -1.57M | -1.26M | 5.70M | -1.86M | -1.26M | 41.30K | -1.10M | -818.39K | -565.34K | -3.25M | -908.29K | -2.71M | -4.52M | -2.79M | -2.48M | -4.68M | -6.36M | -2.82M | -2.46M | -1.88M | -2.08M | -2.18M | -2.52M | -1.87M | -1.63M |
| Diluted EPS | - | - | - | - | 0.04 | - | 0.11 | 0.01 | -0.02 | -0.09 | -0.09 | -0.13 | -0.09 | -0.26 | -0.31 | -0.11 | -0.07 | 0.16 | -1.09 | -0.67 | -0.03 | -0.60 | -0.48 | -0.20 | - | - | - | - | -2.73 | -1.46 | -2.31 | -3.04 | -1.30 | -9.21 | -3.72 | -43.10 | -14.58 | -0.97 | -10.81 | -1.08 |
| R&D Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 50.96K | 63.30K | 157.95K | 879.84K | 1.22M | 1.96M | 2.12M | 2.06M | 1.83M | 2.40M | 1.28M | 506.15K | 565.00K | 802.72K | 746.37K | 1.26M | 402.42K | 345.97K |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | 36.15M | 48.59M | 43.00M | 39.91M | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | 6.93M | 10.24M | 8.98M | 8.15M | - | - | - | - | - | - |
| Operating Income | -35.88K | -31.39K | -22.69K | 27.21K | 32.81K | -5.38M | -10.90M | -7.15M | -2.30M | -5.62M | -64.62M | -27.42M | -16.45M | -9.63M | -8.77M |
| Net Income | -39.44K | -33.38K | -24.62K | -161 | -33.64K | -2.78M | -9.07M | -16.90M | -2.41M | -6.86M | -48.98M | -18.47M | -17.29M | -9.57M | -8.77M |
| Diluted EPS | - | - | - | - | - | -0.21 | -0.75 | -20.47 | -2.83 | - | - | -13.00 | -121.29 | -228.48 | -36.24 |
| R&D Expense | - | - | - | - | - | - | - | - | - | 174.08K | 4.79M | 8.03M | 7.25M | 2.84M | 2.78M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 1.13K | 22.45K | 5.60K | 4.47K | 5.08K | - | 39.51M | 52.20M | 29.64M | 108.79K | 4.10M | 26.72M | 19.55M | 4.30M | 3.08M | 5.10M |
| Total Equity | -10.07K | -49.52K | 4.55K | -20.07K | -20.23K | -3.87K | 258.53K | 11.66M | 19.45M | -65.45K | -1.81M | 3.42M | 22.31M | 14.67M | 1.96M | 1.59M | 4.18M |
| Cash & Equivalents | 1.79K | 1.13K | 18.23K | 1.38K | 249 | 5.08K | 1.88M | 1.38M | 4.88M | 1.37M | 431.40K | - | - | - | - | - | - |
| Long Term Debt | - | - | - | - | - | - | - | 1.54M | 1.13M | 0 | 740.34K | - | - | - | - | - | - |
| Total Liabilities | - | - | - | - | - | - | - | 27.84M | 32.75M | 18.88M | 1.92M | 681.25K | 4.41M | 4.00M | - | - | - |
| Current Liabilities | - | 50.64K | 17.89K | 25.67K | 24.70K | 8.96K | - | 12.71M | 30.37M | 14.69M | 14.38M | 681.25K | 2.74M | 4.00M | 2.34M | 1.49M | 918.40K |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -40.67K | -30.35K | -24.85K | -21.63K | -43.16K | -2.70M | -2.74M | -2.57M | -647.86K | -3.89M | -11.46M | -17.15M | -14.09M | -7.73M | -8.14M |
| Investing Cash Flow | - | - | - | - | - | -6.59M | -169.86K | -3.64M | -284.33K | -44.14K | 2.19M | -584.16K | 11.67K | - | - |
| Financing Cash Flow | 40.00K | 47.45K | 8.00K | 20.50K | 48.00K | 8.80M | 6.41M | 2.69M | 560.00K | 5.53M | 24.90M | 18.18M | -1.34M | 7.67M | 10.58M |
| Capital Expenditure | - | - | - | - | - | - | - | - | - | - | -189.72K | -584.16K | -5.18K | - | - |
| Free Cash Flow | - | - | - | - | - | - | - | - | - | - | -11.65M | -17.73M | -14.10M | - | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | 19.2% | 21.1% | 20.9% | 20.4% | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | -14.9% | -22.4% | -16.6% | -5.8% | - | - | - | - | - | - |
| Net Margin % | - | - | - | - | - | -7.7% | -18.7% | -39.3% | -6.0% | - | - | - | - | - | - |
| ROE % | 79.7% | -732.8% | 122.7% | 0.8% | 869.1% | -23.8% | -46.7% | 25,815.9% | 133.1% | -201.0% | -219.6% | -125.9% | -883.9% | -601.1% | -210.0% |
| ROCE % | 72.5% | -689.2% | 113.1% | -134.5% | -847.6% | -20.1% | -49.9% | -47.8% | 16.1% | -164.5% | -269.5% | -176.2% | -840.8% | -604.7% | -210.0% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Sio Capital Management, LLC | 4.02% | 180.00K | $291.60K |
| 2 | Ikarian Capital, LLC | 2.23% | 100.00K | $162.00K |
| 3 | AdvisorShares Investments, LLC | 0.79% | 35.42K | $57.38K |
| 4 | Renaissance Technologies, LLC | 0.72% | 32.06K | $51.93K |
| 5 | Armistice Capital, LLC | 0.71% | 32.00K | $51.84K |
| 6 | Boothbay Fund Management, LLC | 0.67% | 30.14K | $48.83K |
| 7 | Xtx Topco Ltd | 0.42% | 18.99K | $30.76K |
| 8 | HRT Financial LP | 0.35% | 15.46K | $25.04K |
| 9 | Vanguard Capital Management LLC | 0.33% | 14.91K | $24.16K |
| 10 | Citadel Advisors Llc | 0.31% | 13.96K | $22.62K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ENVB
Enveric Biosciences Announces Withdrawal Of Petition Against Its Patent — ENVB Stock Rises - Stocktwits
<a href="https://news.google.com/rss/articles/CBMi0gFBVV95cUxQQlhNUUFQM3hQc05ocnFucTAteG8zQkRiVHl5MVlYVVQwcWZyWWlnV0ZlRURiQ1pfZ0UydkduTG1iN25DZzcwdUJMRWlIaER0cC1kQ28zZmp0a205NEhyT3FXVmdfeUU1ZlRtcjVOSEdnMjhLSHA3YWx1LVlpUi1YUDdyOTdhd3dxZU44ND…
Enveric Biosciences Inc (NASDAQ: ENVB) Share Price, ENVB Stock News, ENVB Share Price & Updates - kalkine.com.au
<a href="https://news.google.com/rss/articles/CBMiVkFVX3lxTE5mWDVESzRSbkxLT3I5NGx2Zk13cHJVcC1GSG1rNTdCSEtocDFWR2VhbkhmZkF4dy1KbW5UMm4yU2xLdFY5Y3pUOEFuOW05UmE1ZVROaTV3?oc=5" target="_blank">Enveric Biosciences Inc (NASDAQ: ENVB) Share Price,…
Enveric's EB-003 Shows Non-Hallucinogenic Profile in Preclinical Data - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiwAFBVV95cUxPZmVTdkJrR3NPV0tITGIwcURhc2ZSS0VyTHRUNkpUTzBOTDdVUGJPRmNQc1laYjdUUzQyS3ZQeHAya1FQZWJkckZqdWc4eEFnbHEzeG9pVFhIWWhtUGVseDBJUlYtRHFIeGFHSFUtTnZ6SGpUMmYtV2RhMnJxak53ZUdySUM4Mk10MXRVdV…
ENVB - Finviz
<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTE4xRU9BUThyRTVocjBzbl9yeU01WlBTcVdyTDlUTzJzZVJvdkp5QU9YVzg1YUt1c1ZsWFB3VmZGNjBMMFNxb0E?oc=5" target="_blank">ENVB</a> <font color="#6f6f6f">Finviz</font>…
ENVB soars 134% as market reacts to private placement closing and warrant-driven trading dynamics - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMizAFBVV95cUxONnhzSnMxMFZUamphZDlCNjdYTmRrN0dMUDk2R24wblU5UVNqVTZQNVlFV0hyMlppNm16bk5CRnlVaS1tdWIwRmg3cDRlcjh3N3NJcjdDSHduWG1iMFlwOHVaS1JoLWE2N084RzlPSG9WY3dKT2MzdWQ1XzQ4Mnp2Snl3c2NNX1I5eUNIMl…
ENVB Stock Spikes As New U.S. Patent Fuels Trading Momentum - timothysykes.com
<a href="https://news.google.com/rss/articles/CBMigAFBVV95cUxOV3pwbU1uQmxBaEN0RVlyYVRMQTl2WTFmQUxxVkJrdEZaTzUzWHN6QV82UWVBQmoxakpYYWRGblFxUnpRdmg5ZmdwTjBsWkNncGRlSDh0RHE2SWl4VlZZeGo1eDRzR2pST2RNR1ZMenUzTWFUY1FOTEFBU0JNa0l4Rg?oc=5" target="_…
ENVB — Frequently Asked Questions
What is the current share price of Enveric Biosciences, Inc. (ENVB)?
As of 2026-09-19 21:16 PDT, Enveric Biosciences, Inc. (ENVB) trades at $1.42 on NasdaqCM. Its 52-week range is $1.27 to $17.40.
What is the market capitalisation of ENVB?
Enveric Biosciences, Inc. (ENVB) has a market capitalisation of $6.36M on NasdaqCM.
What is the P/E ratio of ENVB?
ENVB trades at a trailing price-to-earnings (P/E) ratio of -0.12. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 0.71.
Is ENVB a good stock to buy?
This page provides a data-driven analysis of Enveric Biosciences, Inc. (ENVB), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.